




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 221/12, 221/16, 221/18, A61K 31/47, C07D 491/04, 217/24, 237/32, 475/02 // (C07D 491/04, 317:00, 221:00)		A1	(11) International Publication Number: WO 99/11624
			(43) International Publication Date: 11 March 1999 (11.03.99)
(21) International Application Number: PCT/US98/18195		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 September 1998 (02.09.98)			
(30) Priority Data: 08/922,520 3 September 1997 (03.09.97) US 09/079,509 15 May 1998 (15.05.98) US 09/145,180 1 September 1998 (01.09.98) US			
(71) Applicant: GUILFORD PHARMACEUTICALS INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors: LI, Jia-He; 10195-K Woodlake Drive, Cockeysville, MD 21030 (US). TAYS, Kevin, L.; Apartment 1415, 6847 Old Waterloo Road, Elkridge, MD 21075 (US). ZHANG, Jie; 8513 High Timber Court, Ellicott City, MD 21043 (US).			
(74) Agent: NATH, Gary, M.; Nath & Associates, 6th floor, 1030 15th Street, N.W., Washington, DC 20005 (US).			

(54) Title: OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY



(57) Abstract

Compound, compositions containing compounds, methods of using compounds, and processes of making compounds, of formula (I) containing at least one ring nitrogen, or a pharmaceutically acceptable base or acid addition salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer or mixtures thereof, wherein: X is double-bonded oxygen, or -OH; when R⁷ is present, it is hydrogen or lower alkyl; y represents the atoms necessary to form a fused mono-, bi- or tricyclic, carbocyclic or heterocyclic ring, wherein each individual ring has 5-6 ring member atoms; and Z is (i) -CH²CHR³- wherein R² and R³ are independently hydrogen, alkyl, aryl or aralkyl; (ii) -R⁶C-CR³- wherein R³ and R⁶ are independently hydrogen, lower alkyl, aryl, aralkyl, halo, -NO₂, -COOR⁷, or -NR⁷R⁸ where R⁸ is independently hydrogen or C₁-C₉ alkyl, or R⁶ and R³, taken together, form a fused aromatic ring, wherein each individual ring has 5-6 ring members; (iii) -R²C=N-; (iv) -CR²(OH)-NR⁷; or (v) -C(O)-NR⁷-.